Profile for Australia Patent: 2020227021
✉ Email this page to a colleague
US Patent Family Members and Approved Drugs for Australia Patent: 2020227021
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| ⤷ Start Trial | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| ⤷ Start Trial | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| ⤷ Start Trial | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| ⤷ Start Trial | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| ⤷ Start Trial | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| ⤷ Start Trial | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| ⤷ Start Trial | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
